ALNYLAM PHARMACEUTICALS INC
For the period ended Dec 31, 2023. Filed Feb 15, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 15, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
ITEM 2. PROPERTIES
Our operations are based primarily in Cambridge, Massachusetts; Zug, Switzerland; Maidenhead, United Kingdom; Amsterdam, Netherlands; and Tokyo, Japan. A description of certain of the facilities we lease or own as of January 31, 2024 is included in the table below.
| Location | Primary Use | ApproximateSquare Footage | LeaseExpiration Date | Renewal Option |
|---|---|---|---|---|
| 675 West Kendall Street Henri A. Termeer Square Cambridge, Massachusetts | Corporate headquarters and primary research facility | 295,000 | January 2034 | Two five-year terms |
| 300 Third StreetCambridge, Massachusetts | Office space and additional research facility | 129,000 | January 2034 | Two five-year terms |
| 101 Main StreetCambridge, Massachusetts | Office space* | 61,000 | March 2024 and June 2026 | One five-year term on each lease |
| 20 Commerce WayNorton, Massachusetts | GMP manufacturing | 200,000 | Not applicable | Not applicable |
| 665 Concord AvenueCambridge, Massachusetts | GMP manufacturing** | 15,000 | September 2027 | One five-year term |
| Grafenauweg 46300 Zug, Switzerland | International headquarters | 14,500 | March 2028 | One five-year term |
| Braywick GateBraywick Road, MaidenheadBerkshire, United Kingdom | Office space | 21,500 | May 2026 | None |
| Wisdom Cross Tower Antonio Vivaldistraat 150Amsterdam, Netherlands | Office space | 12,500 | April 2025 | One five-year term |
| Pacific Century Place1-Chome-11-1 Marunouchi Chiyoda-ku Tokyo, Japan | Office space | 16,900 | May 2025 | None |
- We lease office space located on the 12th and 13th floors at 101 Main Street, Cambridge, Massachusetts under a non-cancelable real property lease agreement by and between the Company and RREEF America REIT II CORP. PPP, dated as of April 15, 2015, or the Lease. On September 30, 2020, we entered into a First Amendment to the Lease, pursuant to which the term of the Lease with respect to the 12th and 13th floors was extended for an additional five years, through June 30, 2026. In addition, we have a separate lease agreement for the 10th floor at 101 Main Street, which expires in March 2024 and will not be extended.
** We manufacture ONPATTRO (patisiran) formulated bulk drug product at this location.
In addition to the locations above, we also occupy small offices in multiple locations in and outside of the U.S. to support our operations and growth.
In the future, we may lease, operate, purchase or construct additional facilities in which to conduct expanded research, development and manufacturing activities and support future commercial operations. We believe that the total space available to us under our current leases will meet our needs for the foreseeable future and that additional space would be available to us on commercially reasonable terms if required.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.